0
Obstructive Lung Diseases |

Lung Volume Reduction Coil Sustained Treatment Effectiveness in Heterogeneous and Homogeneous Emphysema

Dirk-Jan Slebos, MD; Stephen Bicknell, MD; Wolfgang Gesierich, MD; Felix Herth, MD; Juergen Hetzel, MD; Martin Hetzel, MD; Romain Kessler, MD; Charles-Hugo Marquette, MD; Michel Pfeifer, MD; Pallav Shah, MD; Franz Stanzel, MD; Christian Witt, MD; Gaetan Deslee, MD
Author and Funding Information

UMC-Groningen, Groningen, Netherlands


Chest. 2013;144(4_MeetingAbstracts):1026A. doi:10.1378/chest.1780087
Text Size: A A A
Published online

Abstract

SESSION TITLE: COPD

SESSION TYPE: Original Investigation Slide

PRESENTED ON: Wednesday, October 30, 2013 at 02:45 PM - 03:45 PM

PURPOSE: The Lung Volume Reduction Coil (LVRC, PneumRx Inc.) is a bronchoscopic implant for the treatment of severe emphysema, proven to be effective in the treatment of severe COPD. To evaluate longer term efficacy and perform subgroup analyses on efficacy in homogeneous disease, four European studies with nearly identical protocols were analyzed out to one year post-treatment.

METHODS: 119 patients (mean age: 61 years, mean FEV1: 29%, mean RV: 245% pred., mean 6MWT 313m) were treated by bilateral LVRC performed in two separate procedures in two contralateral lobes, with follow-up at 6 months and one year. A post-hoc blinded CT analysis was performed on a subset of data I) by a digital lobar CT emphysema score assessing the percentage destruction below -950HU with a <25% difference between ipsilateral lobes defining homogeneous emphysema, and II) by a visual pattern approach grading from 0 (no damage) to 4 (bullous disease) with a difference of ≤1 point defining homogeneous emphysema.

RESULTS: 2311 LVRCs were placed in 238 procedures (mean 9.7±1.6 per lobe). Serious adverse events (SAE) in the 30 days following treatment included 13 COPD exacerbations (5.5%), 1 hemoptysis (0.5%), 11 pneumonia (4.6%), 9 pneumothorax (3.8%), no deaths or acute respiratory failure. All SAEs resolved with standard care. Effects of LVRC treatment at 6 and 12 months showed significant and sustained mean efficacy: ΔFEV1: +14.9%±22 and +13.2%±27; ΔRV: -0.59L ±0.76 and -0.52L ±0.77; Δ6MWD: +44m±67 and +51m±62; and ΔSGRQ: -11.2pts±12 and -10pts±12 (p<0.0001 for all values). Post-hoc analysis at 6 months was performed on 63 patients to compare homogeneous and heterogeneous response. Digital CT analyses identified 25 homogenous and 38 heterogeneous cases; the visual approach identified 34 homogeneous and 29 heterogeneous. Both RV, 6MWT and SGRQ responses were similar between the two groups, regardless of the calculation method. Only the FEV1 response differed significantly in favor of the heterogeneous group.

CONCLUSIONS: LVRC treatment results in significant and clinically relevant improvements in exercise capacity, lung function, and quality of life for patients with homogeneous and heterogeneous emphysema. Patient relevant improvements from LVRC treatment are sustained at one year.

CLINICAL IMPLICATIONS: The Bronchoscopic Lung Volume Reduction Coil Treatment is a feasible, safe and effective treatment modality for patients with severe heterogeneous and homogeneous emphysema

DISCLOSURE: Dirk-Jan Slebos: Consultant fee, speaker bureau, advisory committee, etc.: DJS has been on advisory board meetings of PneumRx and received travel support from PneumRx for presentation of scientific data. The following authors have nothing to disclose: Stephen Bicknell, Wolfgang Gesierich, Felix Herth, Juergen Hetzel, Martin Hetzel, Romain Kessler, Charles-Hugo Marquette, Michel Pfeifer, Pallav Shah, Franz Stanzel, Christian Witt, Gaetan Deslee

No Product/Research Disclosure Information


Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543